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Abstract
Patients infected with HIV treated with highly active antiretroviral therapy (HAART) frequently develop body
physical changes (BPC) that have an important psychosocial burden. The purpose of this study was to determine
the prevalence of BPC observed by HIV-infected patients and their attending physicians and to assess the impact
BPC had on daily life. In this epidemiologic multicenter study, patients with HIV infection and their treating
physicians filled out parallel questionnaires about their perceptions of specific BPC and their impact on daily
activities. A total of 965 patient–physician questionnaires were collected across 98 health centers. Patient’s mean
age was 43.7 8.5 years and 72.6% were men. Adjusted prevalence of perceived BPC by patients and physicians
was 55.1% (95% confidence interval [CI]: 52.0–58.1) and 55.2% (95% CI: 52.1–58.2), respectively ( p¼ 1.000).
Overall patient-physician agreement concerning perception of BPCwas 83% ( p< 0.0005). The most common BPC
was lipoatrophy, described by 46.8% (95% CI: 43.7–49.8) of patients and 49.4% (95% CI: 46.3–52.5) of physicians
( p¼ 0.033) followed by lipohypertrophy. No gender differences were observed in the global prevalence of BPC
( p¼ 0.649). However, significantly more women reported lipoatrophy of the lower limbs ( p¼ 0.009) and but-
tocks ( p¼ 0.007), as well as lipohypertrophy ( p¼ 0.007), than men; 58.2% (95% CI: 54.0–62.4) patients noted that
BPC negatively affected their daily activities. This study reflects the high prevalence of patient and physician-
perceived BPC in the HIV population, and the adverse impact on daily life. Physicians should be aware of the
psychosocial consequences of BPC in HIV patients in order to improve patient well-being.
Introduction
Before the advent of highly active antiretroviral ther-apy (HAART), patients with HIV infection developed
physical manifestations related to the viral infection and
AIDS. These symptoms were grouped under the name of
wasting syndrome, which involved a progressive loss of lean
body mass with preservation of body fat.1,2 Patients also
developed other changes in appearance associated with the
acquisition of opportunistic infections such as herpes simplex,
oral candidiasis, hairy leukoplakia and molluscum con-
tagiosum, and rare tumors like Kaposi’s sarcoma.3–5 These
conditions were often used as indicators of advanced disease,
and their connection with AIDS was a constant reminder of
the fatal and transmissible nature of the disease that these
patients were carrying.6,7
The situation changed with the introduction of HAART,
which markedly reduced opportunistic infections and HIV-
related morbidity and mortality, as well as the outward signs
associated with the development of AIDS.8,9 On the other
hand, the transformation of this fatal disease into a chronic
illness led to the emergence of metabolic complications
secondary to long-term HAART use. In effect, a clinical syn-
drome consisting of peripheral lipodystrophy, hyperlipid-
emia, diabetes, and insulin resistance was described in 1998 in
HIV patients receiving at least one protease inhibitor (PI).10
Since then, different risk factors, includingHIV infection itself,
have been identified as risk factors for the development of
such syndrome.11–13 Noteworthy, the number of studies as-
sessing HAART-associated metabolic disorders has increased
steadily, leading to the identification of additional alterations
affecting physical appearance.14–16 Frequent physical changes
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related with HAART include lipodystrophy, a wide range of
dermatologic changes, and jaundice.14
Lipodystrophy is a disorder characterized by an abnor-
mal distribution of subcutaneous fat, and includes peripheral
fat loss (lipoatrophy) in the arms, legs, face and buttocks,
and lipohypertrophy (fat accumulation) in the trunk, chest,
breasts, neck, or other areas of the body.17,18 In addition,
lipodystrophy has been associated with other metabolic
features, including disturbances in lipid and glucose metab-
olism, mitochondrial toxicity, and elevated hepatic transam-
inases.17,19 Although the prevalence of lipodystrophy varies
widely, from around 7% to 84%20 depending on the diag-
nostic criteria used, the overall prevalence of at least one
physical change is approximately 50%.21,22 The etiology of
lipodystrophy is multifactorial, involving many overlapping
risk factors related to the duration of HIV disease, degree of
viral suppression, CD4 count at HAART initiation, gender,
age, and duration of exposure to HAART.17,23–28 Visible
changes in fat distribution appear early after the start of
therapy, within 3 months to 1 year according to different
studies, and can be progressive.18,25,26 Some nucleoside
reverse transcriptase inhibitors (NRTIs), particularly thymi-
dine analogues, have been strongly associated with lipody-
strophy, especially lipoatrophy, but currently, most of the
available classes of antiretroviral drugs have been found
to be involved with the abnormal fat distribution in HIV
patients.29–33
Dermatologic disorders constitute another group of
appearance-related side effects of HAART. Although their
causes may be difficult to determine because HIV patients
often take antiretrovirals in conjunction with other drugs,
certain antiretroviral agents are associated with specific cu-
taneous manifestations. Skin rashes have been reported in
association with abacavir, non-NRTIs, and some PIs. Skin and
nail hyperpigmentation has been observed with emtricitabine
and zidovudine use, and jaundice and conjunctival pigmen-
tation secondary to hyperbilirubinemia are side effects ob-
served with atazanavir and indinavir use.14,34,35
Most of these antiretroviral-induced physical changes
usually occur soon after the start of therapy and, with the
exception of lipodystrophy, are usually reversible or treatable.
Fat changes are not easily treatable, and might even cause
chronic disfigurement and pain.36 Current strategies for the
treatment of lipodystrophy involve regimen switching, for
example NRTI sparing, and reconstructive-cosmetic tech-
niques, such as facial lipofilling, which has shown promising
results in the long-term treatment of this condition.14,37
Although much of current research has focused on those
alterations that increase the risk ofmortality, the development
of appearance-related changes can be stigmatizing and so-
cially distressful, producing a significant impact on quality of
life (QOL),38,39 which can lead to decreased adherence to
therapy, suboptimal drug levels, and development of drug
resistance.40,41 Moreover, a study demonstrated that HIV-
infected patients were willing to trade length of life for the
avoidance of appearance-related adverse drug effects.42
Given the importance of the timely recognition of body
physical changes (BPC) caused by HAART, we sought to
determine the prevalence of BPC as perceived by patients
with HIV infection, and compared it to the prevalence of BPC
as perceived by their treating physicians. Other objectives of
this study were to compare the perception of the types of BPC
perceived between patients and physicians, and the impact
that BPC had on daily life according to gender.
Patients and Methods
Study design
This epidemiologic study consisted of a stratified multi-
stage probabilistic survey to evaluate the prevalence of per-
ceived BPC by HIV patients and their treating physicians.
Patients were eligible to be included if they had documented
HIV infection andwerewilling to participate in the study. The
study protocol was approved by the Ethics Committee of
Hospital Clı´nico San Carlos (Madrid), and an informed con-
sent was obtained from all patients before they were included
in the study.
Study procedures
Data were gathered throughout several health centers in
Spain. The survey consisted of two parallel questionnaires
designed specifically for this study, which were to be com-
pleted simultaneously, but independently, by the physician
for a specific patient and by that particular patient during a
single visit. Both questionnaires included an initial section
where baseline patient characteristics were recorded, includ-
ing age, gender, route of HIV infection, duration of HAART,
route of infection and occupational status. Subsequently, pa-
tients and physicians were asked if they had noted the pres-
ence of BPC since the start of HAART; if the answer was ‘‘no,’’
the questionnaire ended. If, on the other hand, the physician
and=or the patient answered ‘‘yes,’’ they proceeded to provide
details about these changes, which included the perception of
changes in skin and conjunctival pigmentation, and whether
or not they had perceived fat loss in the face, upper and lower
limbs and buttocks, or fat accumulation in the neck, lower
back, chest, and trunk. In addition, patients and physicians
were asked to provide a subjective rating of the severity of the
fat loss or accumulation (mild, moderate or severe). Finally,
physicians were asked for how long had they noticed the
presence of BPC in their patients (less than 6 months ago, 6 to
12 months ago, or more than 12 months ago), and patients
were asked if the presence of BPC had influenced in any way
the following aspects of their daily life: mood, daily activities,
personal relationships, and self-esteem.
Physical changes were defined as the perception of an in-
crease (lipohypertrophy) or reduction (lipoatrophy) in bodily
fat of whatever severity in at least one of the abovementioned
body parts.
Statistical analysis
The primary objective of this study was to estimate the
prevalence of BPC perceived by HIV-positive patients re-
ceiving HAART and their attending physicians, which had
been previously estimated as greater than or equal to 25%,
with a relative error less than or equal to 10%. Considering a
finite population of 60,000 HIV-seropositive patients receiv-
ing HAART, and a design effect of 15%, a sample size of 813
evaluable patients was calculated. In addition, taking into
account a phenomenon of nonresponse, and lack of evalu-
ability due to any cause, the sample size was increased in 20%
to 1016 patients and rounded to 1020. Secondary objectives
were to compare the perception of BPC between patients and
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physicians, to compare the prevalence of BPC in men and
women, and to determine whether subjective perceptions of
its importance were gender-specific.
In order to perform a stratified, multistage study, 17 re-
gions were grouped into 12 strata, and the number of patients
and centers involved in each stratum was calculated accord-
ing to the overall HIV population in the area, with an overall
sampling fraction of 0.017 (0.014–0.026). In the first stage, 102
health centers or hospitals were randomly selected with a
probability proportional to the number of HIV patients fol-
lowed up during the last year. In the second stage, attending
physicians were selected by simple random sampling from
each participating center. Finally, in the third stage, 10 pa-
tients from those scheduled by the physician during the study
period ( January 13 until March 18, 2008) were selected by
systematic sampling to fill out the questionnaire. There was
no reposition of patients who refused to participate in the
study.
Qualitative variables are shown as absolute and relative
frequencies, and adjusted percentages with 95% confidence
interval (CI) considering the entire study population overall
or per gender. Impact on daily life was only assessed in pa-
tients (overall and per gender) who reported having per-
ceived BPC. Continuous variables were described usingmean
and standard deviation. Degree of patient–physician agree-
ment was measured using Cohen’s k. Comparison of per-
centages between independent groups was performed with
the w2 test, and within the same group with the McNemar test
or generalized marginal homogeneity test. To study the as-
sociation between BPC and duration of HAART treatment,
quartiles of time under HAARTwere calculated and classified
as follows: less than three years, from three to seven years,
from seven to ten years, and more than ten years. Statistical
analyses were carried out using SPSS v15.0 software (SPSS
Inc., Chicago, IL). Statistical significance was set at p< 0.05.
Results
Description of participants
Between January and February 2008, a total of 965 patient–
physician questionnaires were collected across 98 health
centers. Mean age of the patients was 43.7 8.5 years. Seven
hundred one patients surveyed (72.6%) were men and 255
(26.4%) women; gender was not reported in nine subjects.
Nine hundred eight patients (94.1%) acquired HIV infection
through a single route, either through intravenous drug use
(39.0%), homosexual (26.9%) or heterosexual contact (25.9%).
Mean time of HAARTwas 88.3 55.5 months. Of the patients
included in the study, 74.3% had received HAART for a pe-
riod longer than three years, and 26.3% had received HAART
for more than 10 years. Regarding occupational status, 627
(65.0%) were currently employed, 85 pensioners or retired
(8.8%), 57 unemployed (5.9%), and 31 students (3.2%). Details
of baseline patient characteristics are shown in Table 1.
Perception and severity of BPC by patients
and physicians
There was a concordance of 88.3% in the perception of BPC
between physicians and their corresponding patients
(k¼ 0.682; p< 0.0005); in other words, most physicians and
patients agreed that they had developed BPC. On the con-
trary, 7.7% of the patients considered they had not developed
BPC, while their treating physicians thought they had, and
7.8% of the patients perceived they had developed BPC, while
their treating physicians thought they had not. More than
half of the patients (55.1%; 95% CI: 52.0–58.1) perceived
they had suffered BPC since they started receiving HAART;
similarly, more than half of the physicians (55.2%; 95% CI:
52.1–58.2) perceived their patients had developed BPC. No
significant differences were detected between these percent-
ages ( p¼ 1.000). Themost common BPC identified by patients
and physicians was lipoatrophy, although it was mentioned
by significantly more physicians (49.4%; 95% CI: 46.3–52.5%)
than patients (46.8%; 95% CI: 43.7–49.8%; p¼ 0.033). The face
was the body part most affected by lipoatrophy, followed
closely by the lower limbs, buttocks and upper limbs. No
significant differences were observed between patient and
physician perceptions regarding the body part affected by
lipoatrophy (Table 2). Lipohypertrophy was the next BPC
most frequently noted by patients and also by physicians. The
percentage of patients mentioning lipohypertrophy differed
significantly from the percentage reported by physicians
(28.7% [95% CI: 25.9–31.4] versus 25.7% [95% CI: 23.0–28.4];
p¼ 0.032). The trunk was the body part most commonly af-
fected by lipohypertrophy, perceived by 24.9% (95% CI: 21.3–
28.5) of the patients and 22.8% (95% CI: 19.3–26.2) of the
physicians, followed by the chest, neck and lower back. There
were no significant differences between frequencies observed
Table 1. Baseline Patient Characteristics (n¼ 965)
Characteristics n %
Age (years)
Mean ( SD) 43.7 ( 8.5)
Gender
Male 701 72.6
Route of infection
Single route of infection
IDU 376 39.0
Homosexual contact 260 26.9
Heterosexual contact 250 25.9
Other 22 2.3
Two routes of infection
Heterosexual contactþ IDU 12 1.2
Heterosexual contactþhomosexual 12 1.2
Homosexual contactþ IDU 4 0.5
Not reported 29 3.0
Mean time of HAART (months) 88.3 55.5
Duration of HAART (years)
< 3 210 21.8
3–7 244 25.3
7–10 219 22.7
> 10 254 26.3
Not reported 38 3.9
Occupational status
Employed 627 65.0
Pensioner=retired 85 8.8
Unemployed 57 5.9
Student 31 3.2
Other 141 14.6
Not reported 24 2.5
HAART, highly active antiretroviral therapy; IDU, intravenous
drug use; SD, standard deviation.
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by patients and physicians (Table 2). Skin pigmentation
changes were perceived significantly less often by physicians
than by patients (2.4% [95% CI: 1.4–3.3] versus 5.9% [95% CI:
4.5–7.4]; p< 0.0005). No significant differences were observed
regarding conjunctival pigmentation, which was noted by
3.9% (95%CI: 2.7–5.1) of patients and 3.1% (95%CI: 2.1–4.2) of
physicians (Table 2).
To the question ‘‘For how long have you noticed the pres-
ence of BPC on your patient,’’ 79.2% (95% CI: 76.0–82.4) of the
physicians answered they had noticed these changes for more
than 1 year.
Regarding HAART duration, there was a significant asso-
ciation between the perception of BPC and the duration of
HAART exposure ( p< 0.0005). Overall, 19.8% (95% CI: 16.4–
23.2) of patients on HAART for more than 10 years perceived
BPC compared to 4.9% (95% CI: 3.6–6.3) of patients who had
been on HAART for less than 3 years. McNemar’s test did not
evidence significant differences between patients’ and phy-
sicians’ perception in any of the time of HAART exposure
groups (<3 years, p¼ 0.180; 3–7 years, p¼ 0.072; 7–10 years,
p¼ 0.118; and >10 years, p¼ 0.417; Fig. 1).
In relation to the severity of lipodystrophy-related BPC,
most patients and physicians considered the changes to be
mild or moderate, regardless of whether the BPC was lipoa-
trophy or lipohypertrophy, or of the body region affected
(Table 3). The marginal homogeneity test only showed sig-
nificant differences between the severity of lipohypertrophy
affecting the trunk ( p¼ 0.003) and the chest ( p¼ 0.047), re-
ported by patients and physicians, reflecting the similarity
between patient’s and physician’s assessment of the perceived
severity of BPC.
Perception of BPC between men and women
No significant differences were observed in the over-
all prevalence of BPC perceived by men (54.7%; 95% CI:
51.1–58.3) and women (56.9%; 95% CI: 50.8–63.0; p¼ 0.649).
However, regarding specific BPC, significantly more women
reported lipoatrophy of the lower limbs (42.7% versus 33.7%;
p¼ 0.009) and buttocks (41.5% versus 32.3%; p¼ 0.007), as
well as overall lipohypertrophy (34.7% versus 26.5%; p¼
0.007), than men. No significant differences were observed
Table 2. Comparison of Body Physical Changes Perceived by Patients and Physicians (n¼ 965)
Event
Patients Physicians McNemar’s test
n Adjusted % 95% CI n Adjusted % 95% CI p
Overall BPC 539 55.1 52.0–58.1 542 55.2 52.1–58.2 1.000
Lipoatrophy 456 46.8 43.7–49.8 485 49.4 46.3–52.5 0.033a
Face 38.7 34.7–42.7 42.8 38.7–46.8 0.417
Upper limbs 30.1 26.3–33.9 30.6 26.8–34.4 0.551
Lower limbs 36.4 32.4–40.3 36.6 32.6–40.5 0.868
Buttocks 35.1 31.2–39.1 34.8 30.9–38.8 1.000
Lipohypertrophy 280 28.7 25.9–31.4 252 25.7 23.0–28.4 0.032a
Neck 9.0 6.7–11.4 7.9 5.7–10.2 1.000
Lower back 7.0 4.9–9.1 6.3 4.3–8.3 0.735
Trunk 24.9 21.3–28.5 22.8 19.3–26.2 1.000
Chest 8.9 6.6–11.3 8.7 6.4–11.1 0.556
Skin pigmentation changes 60 5.9 4.5–7.4 24 2.4 1.4–3.3 < 0.0005a
Conjunctival pigmentation 38 3.9 2.7–5.1 31 3.1 2.1–4.2 0.230
aStatistically significant ( p< 0.05).
BPC, body physical changes; CI, confidence interval.
FIG. 1. Percentage of patients re-
ferring body physical changes (BPC)
in relation to years of highly active
antiretroviral therapy (HAART)
duration (n¼ 965).
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between changes perceived by men and women regarding
skin pigmentation changes and conjunctival pigmentation
(Table 4).
Impact of BPC on daily life
Three-hundred twenty-four patients (58.2% of those re-
porting BPC; 95% CI: 54.0–62.4) noted that the development
of BPC negatively affected their daily life. When divided ac-
cording to gender, 63.4% (95% CI: 56.3–70.5) of women and
56.1% (95% CI: 51.2–61.1) of men mentioned that BPC had an
impact on their daily life overall, without significant differ-
ences between genders ( p¼ 0.209). Additionally, as for the
effect of BPC on specific aspects of daily life, significantly
more women described mood changes (53.0%; 95% CI: 45.6–
60.4) compared to men (31.5%; 95% CI: 26.8–45.6; p< 0.0005).
Also, significantly more women (32.2%; 95% CI: 24.9–39.5)
noted that BPC affected their self esteem than men (23.2%;
95% CI: 19.1–27.4; p¼ 0.030), whereas the effects of BPC on
daily activities and personal relationships noticed by men
and women were not significantly different ( p¼ 0.2244 and
p¼ 0.355, respectively; Fig. 2).
Discussion
The results of our study demonstrate that BPC perceived by
HIV-infected patients as well as by their treating physicians is
highly prevalent. In fact, the estimated prevalence of per-
ceived BPC doubled the initial statistical estimation of 25%,
underscoring the significance of our findings. The most com-
mon BPC described by patients and physicians was lipoa-
trophy, with estimated prevalence rates of 46.8% and 49.4%,
respectively. Lipohypertrophy was the next BPC most re-
ported by patients and physicians, with prevalence rates of
28.7% and 25.7%, respectively. In relation to lipodystrophy
as a whole, although studies have yielded variable re-
sults,21,41,43–47 those including a similar sample size as the one
used in our study reported prevalence rates of lipodystrophy
perceived by HIV-infected patients that range between 28%
and 49%.43,47 The reason behind these differencesmight be the
lack of an objective definition and measurement of lipody-
strophy,21 and the presence of confounding factors such as
age, gender, and type and duration of HAART.22
When patients and physicians were asked to grade the
severity of lipodystrophic changes, all of themwere regarded,
Table 3. Severity of Lipoatrophy According to Patients and Physicians
Lipoatrophy, n (%)a Lipohypertrophy, n (%)a
Severity Face Upper limbs Lower limbs Buttocks Neck Lower back Trunk Chest
Patients n¼ 381 n¼ 296 n¼ 358 n¼ 346 n¼ 89 n¼ 69 n¼ 245 n¼ 88
Mild 164 (43.0) 147 (49.7) 132 (36.9) 130 (37.6) 43 (48,3) 47 (68.1) 104 (42.4) 51 (57.9)
Moderate 131 (34.4) 103 (34.8) 145 (40.5) 119 (34.4) 21 (23.6) 14 (20.3) 92 (37.6) 21 (23.9)
Severe 86 (22.6) 46 (15.5) 81 (22.6) 97 (28.0) 25 (28.1) 8 (11.6) 49 (20.0) 16 (18.2)
Physicians n¼ 421 n¼ 301 n¼ 360 n¼ 343 n¼ 78 n¼ 62 n¼ 224 n¼ 86
Mild 189 (44.9) 144 (47.8) 132 (36.7) 118 (34.4) 31 (39.8) 45 (72.6) 86 (38.4) 46 (53.5)
Moderate 158 (37.5) 132 (43.9) 179 (49.7) 166 (48.4) 26 (33.3) 15 (24.2) 119 (53.1) 37 (43.0)
Severe 74 (17.6) 25 (8.3) 49 (13.6) 59 (17.2) 21 (26.9) 2 (3.2) 19 (8.5) 3 (3.5)
GMHT p value 0.828 0.227 0.655 0.169 0.633 0.204 0.003b 0.047b
aPercentage of severity grade declared by patients and=or physicians reporting each event.
bStatistically significant ( p< 0.05).
GHMT, Generalized marginal homogeneity test.
Table 4. Comparison of Body Physical Changes Perceived by Men and Women (n¼ 956)a
Event
Men (n¼ 701) Women (n¼ 255)
n Adjusted % 95% CI n Adjusted % 95% CI
McNemar’s test
p
Overall BPC 387 54.7 51.1–58.3 145 56.9 50.8–63.0 0.649
Lipoatrophy 321 45.7 42.1–49.3 128 50.5 44.4–56.6 0.228
Face 38.2 34.2–42.2 39.2 35.2–43.2 0.768
Upper limbs 28.5 24.8–32.3 34.2 30.3–38.1 0.085
Lower limbs 33.7 29.8–37.6 42.7 38.6–46.7 0.009b
Buttocks 32.3 28.4–36.2 41.5 37.4–45.6 0.007b
Lipohypertrophy 188 26.5 23.3–29.8 88 34.7 28.6–40.7 0.007b
Neck 8.4 6.1–10.7 10.4 7.8–12.9 0.335
Lower back 6.3 4.3–8.3 17.3 14.2–20.4 < 0.0005b
Abdomen 22.7 19.2–26.1 30.7 26.9–34.6 0.001b
Chest 7.0 4.9–9.1 14.6 11.7–17.5 < 0.0005b
Skin pigmentation changes 40 5.6 3.9–7.3 19 6.8 3.8–9.8 0.321
Conjunctival pigmentation 27 3.7 2.3–5.1 10 3.8 1.4–6.1 0.960
aGender was not reported in 9 subjects.
bStatistically significant ( p< 0.05).
BPC, body physical changes; CI, confidence interval.
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for the most part, as mild or moderate. Lipodystrophy is a
complex syndrome, and its etiology is far from understood,17
and so its treatment is equally complex. Antiretroviral switch-
ing has been rigorously studied and, although results on
improvement of lipohypertrophy are confusing or even con-
tradictory,48 current data on improvement of lipoatrophy
indicate that switching to less toxic NRTIs (e.g., avoiding
thymidine analogue NRTIs) such as abacavir or tenofovir
leads to a limb fat gain, but this fat improvement is slow and
incomplete.49–51 Thus, given the difficulty of reverting lipo-
dystrophic changes, and since there are less toxic therapeutic
options available, it seems reasonable to prevent the devel-
opment of this disorder at its earliest and less severe stages
than to wait until it becomes clinically evident.
In our study, significantly more patients perceived skin
pigmentation changes than physicians. Some of the reasons
behind this might be that dermatological conditions are less
evident than other BPC, and hence are perceived less fre-
quently by the attending physician. On the other hand, con-
junctival pigmentation was perceived by almost as many
patients as physicians. Jaundice and conjunctival pigmenta-
tion, a consequence of hyperbilirubinemia, is a side effect
developed by approximately 30% of patients taking the PI
atazanavir.52 Although these signs are reversible upon dis-
continuation, and elevations in unconjugated bilirubin do not
seem to produce other significant side effects besides those
related to appearance,52 the presence of jaundice may lead to
esthetic concerns and social distress.
One of the objectives of this study was to investigate the
impact that the development of BPC has on daily life of HIV-
infected patients. Given the high prevalence of BPC found in
our study population, this matter is worth considering. Our
results showed that more than half (58.2%) of the patients
reporting BPC thought that these affected their daily life; this
effect seemed to be greater within the female population, and
significantly greater for mood and self-esteem implications
with respect to men. Although few studies have assessed this
issue, those that have done so agree that appearance-related
changes do have a significant impact on daily life in HIV-
infected patients.39 The development of lipodystrophy in
HIV-infected patients produces feelings of shame, influences
choice of clothing, disrupts sex life, impairs psychosocial
functioning and generates bodily discomfort, low self-esteem
and depression.38,53 In addition, patients with lipodystrophy
often feel they can be recognized as HIV positive by their
physical appearance,46 a reminder of the early years of AIDS
when BPC developed by HIV-infected patients were recog-
nized as true landmarks of the disease. Our results confirm
these observations, as lipodystrophy had a negative effect on
body image perception and self-esteem, which could even-
tually lead to stigmatization of interpersonal and intimate
relations, as has been demonstrated by other authors.44,54,55
Above all, several studies have proven that the negative ef-
fects that BPC have on daily life are an important source of
reduced adherence to therapy,40,41,56 particularly in patient-
perceived BPC in comparison to clinically diagnosed BPC.57
We acknowledge that the results of this observational
study should be interpreted in the light of potential limi-
tations inherent in epidemiologic studies; also, the use of
validated health-related quality of life questionnaires could
have been helpful to determine with certainty whether HIV-
infected patients with BPC have a worse quality of life and
functionality than patients without BPC. Nevertheless, our
study provides significant data on BPC prevalence in the HIV
population on HAART in our country, which had not been
previously estimated. Furthermore, we consider this study is
of special relevance due to the lack of trials assessing daily life
in HIV-infected patients, and the growing interest in the well-
being of patients with this disease in the HAART era. Thus,
based on these two main outcomes, it is of special importance
that physicians treating HIV subjects actively search for BPC
and ask their patients about the impact of BPC on their daily
lives.
Finally, health professionals should be aware of the psy-
chosocial consequences of BPC in HIV patients in order to
reduce potential negative effects on therapy, such as reduced
FIG. 2. Impact of body physical changes on daily life among men and women reporting body physical changes (BPC).
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adherence to HAART. A reasonable strategywould be to start
therapy early with a regimen not associated with lipody-
strophy, or to switch to less toxic antiretrovirals as they be-
come available.
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